PriceTargets.com logo

HUTCHMED - HCM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $29.70
  • Forecasted Upside: 61.33%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$18.41 As of 04/24/2024 01:00 AM ET
▲ +0.16 (0.88%)

This chart shows the closing price for HCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New HUTCHMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCM

Analyst Price Target is $29.70
▲ +61.33% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for HUTCHMED in the last 3 months. The average price target is $29.70, with a high forecast of $50.00 and a low forecast of $17.00. The average price target represents a 61.33% upside from the last price of $18.41.

This chart shows the closing price for HCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 4 contributing investment analysts is to moderate buy stock in HUTCHMED. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
12/18/2023Cantor FitzgeraldReiterated RatingOverweightLow
11/24/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$22.10Low
11/10/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$15.00 ➝ $17.00Low
9/5/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
8/2/2023CitigroupInitiated CoverageBuyLow
7/24/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$50.00Low
3/1/2023Cantor FitzgeraldReiterated RatingOverweightLow
8/9/2022The Goldman Sachs GroupBoost TargetNeutral$14.00 ➝ $16.00Low
8/2/2022The Goldman Sachs GroupLower TargetNeutral$16.00 ➝ $14.00Low
5/4/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
9/22/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$46.00High
8/3/2021Jefferies Financial GroupInitiated CoverageBuy$52.00Low
7/13/2021Cantor FitzgeraldBoost TargetOverweight$40.00 ➝ $45.00Low
2/16/2021MizuhoInitiated CoverageBuyLow
10/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$40.00Medium
3/12/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
2/20/2020The Goldman Sachs GroupInitiated CoverageBuyLow
11/19/2019CLSAInitiated CoverageBuyLow
10/23/2019Bank of AmericaInitiated CoverageBuy$35.00 ➝ $29.00High
7/5/2019MacquarieInitiated CoverageOutperform ➝ OutperformLow
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.39 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 4 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

HUTCHMED logo
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Read More

Today's Range

Now: $18.41
Low: $18.10
High: $18.72

50 Day Range

MA: $16.32
Low: $13.67
High: $18.56

52 Week Range

Now: $18.41
Low: $10.68
High: $20.73

Volume

57,758 shs

Average Volume

122,455 shs

Market Capitalization

$3.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of HUTCHMED?

The following Wall Street sell-side analysts have issued research reports on HUTCHMED in the last twelve months: Cantor Fitzgerald, Citigroup Inc., Deutsche Bank Aktiengesellschaft, StockNews.com, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for HCM.

What is the current price target for HUTCHMED?

3 Wall Street analysts have set twelve-month price targets for HUTCHMED in the last year. Their average twelve-month price target is $29.70, suggesting a possible upside of 61.3%. Cantor Fitzgerald has the highest price target set, predicting HCM will reach $50.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $17.00 for HUTCHMED in the next year.
View the latest price targets for HCM.

What is the current consensus analyst rating for HUTCHMED?

HUTCHMED currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for HCM.

What other companies compete with HUTCHMED?

Other companies that are similar to HUTCHMED include Amicus Therapeutics, Biohaven, Bausch Health Companies, Xenon Pharmaceuticals and Crinetics Pharmaceuticals. Learn More about companies similar to HUTCHMED.

How do I contact HUTCHMED's investor relations team?

HUTCHMED's physical mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company's listed phone number is 852-2121-3888 and its investor relations email address is [email protected]. The official website for HUTCHMED is www.chi-med.com. Learn More about contacing HUTCHMED investor relations.